Drug intelligence / Profile preview

DV281 + nivolumab

Development stage: Unknown
Lead developer: Dynavax Technologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Inhalation, Intravenous

Overview

DV281 + nivolumab is a combination therapy consisting of DV281, a TLR9 agonist administered via inhalation, and nivolumab, a PD-1 inhibitor administered intravenously. DV281 is designed specifically for focused delivery to primary lung tumors and lung metastases. This combination aims to enhance immune response against cancer cells by combining localized innate immune stimulation (DV281) with checkpoint blockade (nivolumab). The combination was studied in a Phase Ib clinical trial for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Targets

TLR9 (Toll-like receptor 9)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on DV281 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DV281 + nivolumab.

Explore the full profile